Mylk2: Potential Drug Target Or Biomarker (G85366)

Target Name: MYLK2

NCBI ID: G85366

MYLK2

Mylk2: Potential Drug Target Or Biomarker

Mylk2 (MYLK2_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the myliodysplastic leukemia (MLD) family of proteins, which are known to play a role in the development and progression of various types of cancer.

One of the main functions of Mylk2 is to promote the formation of normal tissues during fetal development and wound healing. This protein is involved in the development and maintenance of the myocardium, which is the heart muscle, as well as the formation of the liver and pancreas. It is also involved in the regulation of cell growth and differentiation, and has been shown to play a role in the development of various types of cancer.

In addition to its functions during development and wound healing, Mylk2 has also been shown to be involved in the regulation of cancer growth and progression. For example, studies have shown that Mylk2 can promote the growth and survival of various types of cancer cells, and that inhibiting its activity can lead to the death of these cells.

Despite its involvement in the development and progression of cancer, Mylk2 is not considered a potential drug target or biomarker. This is because while it is known to play a role in the regulation of various physiological processes, it has not been shown to interact with any specific molecules or to cause any observable effects in humans.

However, the potential implications of Mylk2 as a drug target or biomarker are significant. Given its involvement in the regulation of cancer growth and progression, it is possible that targeting its activity could be a effective way to treat various types of cancer. Additionally, because Mylk2 is involved in the development and maintenance of tissues during fetal development and wound healing, it is possible that targeting its activity could be a way to treat injuries and diseases that affect these processes, such as wound healing disorders or developmental defects.

In conclusion, Mylk2 (MYLK2_HUMAN) is a protein that is expressed in various tissues of the human body that is involved in the development and maintenance of tissues during fetal development and wound healing. While it is not currently considered a potential drug target or biomarker, its potential implications for the treatment of various types of cancer and injuries and diseases are significant. Further research is needed to fully understand its role and potential as a drug or biomarker.

Protein Name: Myosin Light Chain Kinase 2

Functions: Implicated in the level of global muscle contraction and cardiac function. Phosphorylates a specific serine in the N-terminus of a myosin light chain

The "MYLK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYLK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets